Last updated: October 3, 2026
ELOXATIN is Sanofi’s brand for oxaliplatin, a platinum-based chemotherapy used mainly in FOLFOX regimens for colorectal cancer. Its commercial trajectory follows a standard oncology lifecycle: rapid uptake after U.S. approval in 2002, peak sales before patent expiry, steep erosion after generic entry, and continued clinical use through low-cost injectable versions.
Sanofi no longer reports ELOXATIN as a material standalone product. The brand has largely been replaced by generic oxaliplatin in the United States and other major markets. Current value resides primarily in hospital purchasing, treatment-volume demand, manufacturing reliability, and generic portfolio economics rather than brand pricing power.
What is ELOXATIN and how is oxaliplatin used?
ELOXATIN contains oxaliplatin, an intravenous platinum compound that forms DNA cross-links and inhibits cancer-cell replication. Its principal use is colorectal cancer.
| Attribute |
ELOXATIN / oxaliplatin |
| Active ingredient |
Oxaliplatin |
| Brand owner |
Sanofi |
| Original developer/licensor |
Debiopharm |
| Dosage form |
Intravenous injection or infusion |
| Main indication |
Colorectal cancer |
| Common regimen |
FOLFOX with 5-fluorouracil and leucovorin |
| U.S. approval |
August 9, 2002 |
| FDA application |
NDA 021492 |
| Regulatory category |
Small-molecule oncology drug |
| Biosimilar pathway |
Not applicable |
| Current market structure |
Predominantly generic |
The FDA approved ELOXATIN for use with infusional 5-fluorouracil and leucovorin in metastatic colorectal cancer and later for adjuvant treatment of stage III colon cancer after resection of the primary tumor.[1]
Oxaliplatin is also used in clinical practice for gastrointestinal cancers outside the narrow original label, including gastric, pancreatic, and biliary tract cancers. These uses support demand but do not create the same patent value as an FDA-approved method-of-use claim.
When did ELOXATIN lose exclusivity?
ELOXATIN lost meaningful U.S. market exclusivity after the expiration of its primary composition-of-matter patent and the entry of generic oxaliplatin.
| Milestone |
Date or period |
| U.S. patent grant for oxaliplatin |
February 10, 1998 |
| U.S. FDA approval |
August 9, 2002 |
| U.S. composition patent expiration |
February 10, 2015, subject to applicable regulatory adjustments |
| Generic competition |
Began before or around the end of branded exclusivity, depending on product and market |
| Current status |
Generic-dominated |
The central U.S. patent commonly associated with oxaliplatin is U.S. Patent No. 5,716,988. The patent covered oxaliplatin and related pharmaceutical compositions. Its ordinary 17-year term from issuance would have ended in February 2015. Because the patent issued before the Uruguay Round Agreements Act changed U.S. patent-term rules, its term was generally calculated from issuance rather than the later 20-year-from-priority system.
The product did not retain a durable market monopoly after patent expiry. Unlike some biologics and specialty medicines, oxaliplatin had no long-term regulatory exclusivity barrier capable of sustaining brand economics after generic approval.
What patents protect ELOXATIN?
ELOXATIN’s original patent estate centered on the oxaliplatin molecule, pharmaceutical compositions, and certain manufacturing or formulation concepts.
Core patent protection
| Patent area |
Commercial relevance |
Current value |
| Oxaliplatin composition patent |
Protected the active compound |
Expired in the United States |
| Pharmaceutical composition claims |
Covered drug-containing compositions |
Limited after generic entry |
| Manufacturing and stereochemical claims |
Potentially affected production routes |
Relevant only if claims remain enforceable in a particular jurisdiction |
| Method-of-use claims |
Covered cancer treatment applications |
Narrower than composition protection |
| Formulation and container claims |
Could address stability or presentation |
Limited by generic substitution and regulatory requirements |
The commercial barrier was the composition patent, not a complex formulation platform. Oxaliplatin is an injectable small molecule, and its generic development path is less technically difficult than that for a monoclonal antibody, long-acting depot product, or complex inhaled medicine.
Patent risk is now jurisdiction-specific. Expired U.S. composition protection does not eliminate foreign patents, process patents, or litigation rights in countries where patent terms differed. It does, however, remove the principal U.S. barrier to abbreviated new drug applications.
What is the Orange Book status of ELOXATIN?
ELOXATIN is listed in the FDA Orange Book under NDA 021492. The product’s regulatory position is materially different from its historical patent position.
The Orange Book has historically identified oxaliplatin injectable products and relevant patent information associated with the branded NDA. For current commercial analysis, the key point is that the principal U.S. patent barrier has expired and multiple abbreviated new drug applications have been approved.
Generic oxaliplatin products generally rely on the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. Because oxaliplatin is administered intravenously by healthcare professionals, generic substitution is governed by hospital formularies, group purchasing organizations, oncology protocols, and state substitution rules rather than retail pharmacy substitution alone.
How did ELOXATIN sales develop?
ELOXATIN became one of Sanofi’s important oncology products during the 2000s. Sales increased as FOLFOX became a standard colorectal cancer regimen and as adjuvant treatment expanded the eligible patient population.
Sanofi’s historical financial reporting identified ELOXATIN as a major product before generic erosion. Public disclosures place peak annual sales at approximately €1 billion to €1.1 billion during the late 2000s, although reported figures vary by fiscal year, currency translation, geographic scope, and whether the company included related formulation or regional sales categories.[2][3]
Historical commercial trajectory
| Period |
Market position |
Financial effect |
| 2002-2004 |
U.S. launch and clinical adoption |
Rapid revenue growth |
| 2005-2008 |
Broad FOLFOX adoption and expanding indications |
Peak or near-peak branded sales |
| 2009-2012 |
Increasing generic and pricing pressure in some markets |
Declining growth |
| 2013-2015 |
Patent expiry and generic entry |
Accelerated revenue erosion |
| 2016 onward |
Generic-dominated injectable market |
Minimal standalone brand contribution |
ELOXATIN’s revenue concentration was tied to colorectal cancer treatment volumes rather than chronic maintenance therapy. That distinction matters. Oncology products used for finite treatment courses can generate substantial sales at peak, but revenue falls quickly when a lower-cost generic becomes accepted in hospital protocols.
Sanofi does not currently disclose a separate ELOXATIN revenue line in its principal financial reporting. The product therefore should not be modeled as a current material contributor to Sanofi’s consolidated sales without company-specific segment data.
Why did generic competition reduce ELOXATIN revenue so quickly?
Generic oxaliplatin created price competition through several channels:
- Hospitals shifted purchasing toward lower-cost suppliers.
- Group purchasing organizations negotiated volume discounts.
- Oncology practices adopted protocol-level substitution.
- Payers reduced reimbursement differentials between brand and generic products.
- Multiple injectable suppliers competed for contracts.
The product’s intravenous administration strengthened institutional purchasing power. Prescribers typically have less brand attachment to a generic injectable than to an oral targeted therapy. Manufacturing quality, supply continuity, vial configuration, and contract price became more important than brand recognition.
Generic price erosion was not uniform. Shortages, production interruptions, changes in supplier capacity, and oncology drug procurement constraints periodically supported higher prices for available generic inventory. Those effects can improve short-term supplier revenue but do not restore branded ELOXATIN’s former economics.
Which companies compete with ELOXATIN?
The relevant competitors are generic manufacturers rather than branded oncology innovators.
Potential and historical suppliers have included large injectable and generic manufacturers such as Teva, Fresenius Kabi, Pfizer’s Hospira business, Hikma, Sandoz, and other FDA-approved ANDA holders. Supplier participation changes over time as companies enter, exit, or suspend production.
| Competitive factor |
Impact on oxaliplatin market |
| Number of approved ANDAs |
Increases price competition |
| Manufacturing capacity |
Determines supply reliability |
| FDA inspections and remediation |
Can remove or constrain suppliers |
| Drug shortages |
Can temporarily improve pricing |
| Hospital contracts |
Shift share toward reliable vendors |
| Vial size and packaging |
Affects waste and total treatment cost |
The competitive landscape is fragmented, but not every approved supplier consistently markets product. Approval counts therefore overstate active competition. Commercial share depends on current manufacturing status, wholesaler inventory, tender awards, and shortage conditions.
What generic entry risks exist for ELOXATIN?
Generic entry risk is no longer a future event for ELOXATIN in the United States. It is the established market condition.
For manufacturers and investors, the main risks are:
- Continued price compression
- Loss of hospital contracts
- Manufacturing-cost inflation
- FDA compliance actions
- Raw-material shortages
- Product recalls
- Excess capacity among injectable suppliers
- Reimbursement reductions
- Substitution by alternative chemotherapy regimens
For Sanofi, the residual risk is limited brand cannibalization because the brand’s U.S. revenue base has already been substantially eroded. For generic manufacturers, the commercial risk is greater because margins depend on supply discipline and procurement positioning.
Is there biosimilar risk for ELOXATIN?
No. Oxaliplatin is a chemically synthesized small molecule, not a biologic. It is regulated through the generic drug pathway, principally under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
The relevant competitors are ANDA-based generic products, not biosimilars under the Public Health Service Act. This distinction affects development cost, approval timing, interchangeability rules, and litigation strategy.
What patent litigation and Paragraph IV challenges affected ELOXATIN?
Generic oxaliplatin development could involve Paragraph IV certifications against Orange Book-listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. Such a certification can trigger patent litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.
The principal historical litigation risk focused on the scope and validity of oxaliplatin patents and associated pharmaceutical claims. After the core U.S. patent expired, the commercial significance of new Paragraph IV challenges declined sharply.
There is no current indication that ELOXATIN has a commercially significant, unexpired U.S. patent estate capable of blocking ordinary generic oxaliplatin entry. Litigation can still arise over manufacturing patents, labeling, supply agreements, or product quality, but those issues do not recreate the original composition-of-matter monopoly.
What licensing deals supported ELOXATIN?
ELOXATIN originated with Debiopharm and was licensed for development and commercialization to Sanofi, then operating through predecessor entities including Sanofi-Synthélabo and Aventis. The licensing relationship allowed Sanofi to conduct late-stage development, obtain regulatory approvals, and commercialize oxaliplatin internationally.[4]
The economic importance of the deal was highest during the product’s branded period. After generic entry, the value of royalty streams, if any remained under the relevant agreements, would have fallen with branded net sales. Public disclosures do not provide a current standalone royalty figure for ELOXATIN.
How strong is the ELOXATIN patent estate today?
The current patent estate is weak from a U.S. exclusivity perspective.
| Dimension |
Assessment |
| U.S. composition protection |
Expired |
| U.S. generic blocking power |
Low |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Narrow and commercially secondary |
| Manufacturing barriers |
Moderate for quality-controlled sterile production |
| Foreign protection |
Depends on country and patent status |
| Regulatory exclusivity |
Not commercially significant today |
| Brand pricing power |
Low |
The remaining barrier is operational rather than legal. Sterile injectable production requires validated facilities, quality systems, specialized packaging, and reliable supply chains. These requirements can limit the number of active suppliers, but they do not provide Sanofi with exclusive rights.
How does ELOXATIN compare with newer colorectal cancer drugs?
ELOXATIN has a lower price and broader generic availability than newer targeted or biologic therapies. Its clinical role remains important in combination regimens, but its commercial profile is fundamentally different.
| Product category |
Examples |
Exclusivity profile |
Commercial model |
| Generic chemotherapy |
Oxaliplatin |
Expired composition patents |
Volume and procurement |
| Anti-VEGF biologic |
Bevacizumab |
Biologic and biosimilar competition |
Higher unit economics |
| Anti-EGFR antibodies |
Cetuximab, panitumumab |
Biologic exclusivity and biosimilars |
Biomarker-selected use |
| Oral targeted drugs |
Regorafenib, encorafenib combinations |
Small-molecule patents |
Higher price, narrower populations |
| Immunotherapy |
Pembrolizumab, nivolumab |
Biologic exclusivity |
Biomarker and line-of-therapy driven |
Oxaliplatin remains foundational because its clinical utility is supported by established colorectal cancer protocols. Its low cost also makes it economically attractive within combination therapy, even though it no longer generates branded pharmaceutical margins.
What is the outlook for ELOXATIN revenue and market demand?
Demand for oxaliplatin should remain tied to global colorectal cancer incidence, treatment access, guideline use, and availability of competing regimens. The market is mature and largely volume-driven.
The financial outlook is:
- Sanofi brand revenue: negligible relative to peak levels.
- Generic supplier revenue: stable but price-sensitive.
- Market growth: modest, driven mainly by treatment volume and geographic access.
- Margin outlook: constrained by procurement competition.
- Supply outlook: exposed to sterile manufacturing disruptions.
- Innovation outlook: low for the original molecule, with more value in combinations and delivery efficiency.
ELOXATIN is therefore a declining branded asset but a durable generic oncology ingredient. Its commercial value has migrated from patent protection and premium pricing to manufacturing execution, tender access, and supply reliability.
Key Takeaways
- ELOXATIN is Sanofi’s brand of oxaliplatin, an intravenous chemotherapy used primarily in FOLFOX treatment for colorectal cancer.
- U.S. FDA approval occurred in 2002 under NDA 021492.
- The principal U.S. oxaliplatin patent, U.S. Patent No. 5,716,988, expired in 2015.
- Historical peak sales were approximately €1 billion to €1.1 billion annually before generic erosion.
- Sanofi no longer reports ELOXATIN as a material standalone product.
- Generic oxaliplatin, not biosimilar competition, defines the current market.
- Residual commercial barriers are sterile manufacturing, supply reliability, hospital contracts, and procurement economics.
- The current U.S. patent estate has limited ability to block generic entry.
- ELOXATIN remains clinically relevant but has minimal branded financial value.
FAQs
Is ELOXATIN still sold in the United States?
Sanofi’s branded ELOXATIN has been commercially displaced by generic oxaliplatin. Generic products remain available through hospital and specialty oncology channels, subject to supplier status and market conditions.
What is the generic name for ELOXATIN?
The generic name is oxaliplatin. It is supplied as an intravenous product and is commonly used with fluorouracil and leucovorin in FOLFOX regimens.
Can a generic manufacturer launch oxaliplatin without a license from Sanofi?
In the United States, a manufacturer can pursue an ANDA without a Sanofi license after relevant patents and exclusivities no longer block approval. The applicant must satisfy FDA quality, pharmaceutical-equivalence, and bioequivalence requirements.
Does ELOXATIN have orphan-drug exclusivity?
ELOXATIN’s current market position is not protected by commercially meaningful orphan-drug exclusivity. Its principal economic protection came from patent rights and regulatory approval for colorectal cancer indications.
Why can generic oxaliplatin prices rise after patent expiry?
Prices can rise temporarily when sterile injectable suppliers experience manufacturing problems, shortages, recalls, or capacity constraints. Patent expiry increases legal competition but does not guarantee uninterrupted physical supply.
References
- U.S. Food and Drug Administration. (2002). ELOXATIN (oxaliplatin) injection prescribing information.
- Sanofi-Aventis. (2008). Annual report 2008.
- Sanofi. (2012). Annual report 2012.
- Debiopharm. (n.d.). Oxaliplatin and ELOXATIN development history.
- U.S. Patent and Trademark Office. (1998). U.S. Patent No. 5,716,988: Cis-oxalato(trans-l)-1,2-diaminocyclohexane platinum (II) and pharmaceutical compositions.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
